Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

17-02-2021 | ASCO GU 2021 | Conference coverage | Video

Nonmetastatic urothelial cancer: clinical insights into trial data

Speakers: Shilpa Gupta and Petros Grivas

Petros Grivas and Shilpa Gupta discuss the key abstracts in the nonmetastatic urothelial cancer setting, including POUT, CheckMate 274, and SAKK 06/17, sharing their thoughts on how the data inform clinical practice (10:39).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

13-02-2021 | ASCO GU 2021 | Conference coverage | News

CheckMate 274: Adjuvant nivolumab improves muscle-invasive urothelial cancer DFS

13-02-2021 | ASCO GU 2021 | Conference coverage | News

Perioperative durvalumab feasible for muscle-invasive urothelial carcinoma

11-03-2020 | Urothelial cancer | Highlight | News

POUT supports adjuvant chemotherapy as ‘standard of care’ for upper tract UC

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The BLASST-1 trial
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits